Is this the best you Shorties can do, badmouth Raj in a self serving taunt that has no relevance to actual events and use your alias to stick five thumbs up your keysters, hmm - sad.
Yes, indeed, and the company has spread the word widely with a two page detailed summary in the ASH Daily News on pages B-34 and B-35 which is available over the internet.
In previous years, there has been a noticeable biotech runup to ASH followed by a decline. This year is quite different, no runup - so, I wouldn't be at all surprised to have a followup increase in well positioned companies such as Spectrum with under recognized products gaining tracktion.
Besides the fifteen or more ongoing presentations at the Hemotology meeting, Spectrum placed a two page technically detailed summary of vinCRIStine (Marqibo) in the first day's publication - see pages B-34 and B-35.
Barraick and Goldcorp want to sell the Marigold Mine, about 40 miles (64 kilometers) southeast of Winnemucca, Nevada. It produced about 81,000 ounces of gold in the first six months of this year, based on data published on Barrick’s website and in Goldcorp filings. The Hycroft gold mine is located some 54 miles west of Winnemucca. A joint operation might to more economical.
Given the lackluster current gold pricing and the share dumps of the last few sessions, we may see $3.00 pps today which I believe will be the bottom as December sessions will come after the satisfaction of the $16.6M note due Sunday, December 1st.
Someone may be guessing that the need for an anti-nerve gas agent like PRX-105 has diminished due to the Syrian accord. I would not thick such is the case, nor would I ignore PLX-106 or PLX-102.
The ASH meet is the most anticipated medical gathering of the year, particularly for blood related disorders like lymphomas. Spectrum will be a prominent participant.
A small, short blast shook the perennially active Aleutian Island volcano Mount Cleveland overnight. No further signs of "eruptive activity" followed. Stay alert.
What expertise you claim to have is in bioMérieux, a player in infectious disease diagnostics, you need to study up on microRNAs.
Also, the company buried it in their website by subdividing the SEC listings causing news auto scan programs to miss it., tricky boys!
Five years out of date assessment before completion of new extraction mill and higher gold pricing. Desperation will not change the situation, Shortie. ANV will make its Dec 1st bond payment and the stock will move higher.
As likely as a large solid gold meteorite disrupting gold prices. Could happen in your dreams, Shortie.
Detail pricing haven't been given as yet. What is on their SEC filling site has:
We have calculated the securities included in this registration statement by assuming that each share of Series D Preferred Stock is convertible into 411.5226 shares of Common Stock at an assumed conversion price of $2.43 per share of Common Stock, which was the closing price of our Common Stock on The NASDAQ Capital Market on November 18, 2013, and that each Warrant is exercisable for 411.5226 shares of Common Stock at an assumed exercise price per share of $2.67, which is 110% of the closing price of our Common Stock on The NASDAQ Capital Market on November 18, 2013.
We are offering 10,000 units to purchasers in this offering, with each unit consisting of (1) one share of Series D preferred stock which is convertible into that number of shares of our common stock equal to 1,000 divided by the conversion price of the Series D preferred stock and (2) a warrant exercisable for 100% of the number of shares of our common stock issuable upon conversion of a share of Series D preferred stock (at the initial conversion price), at an exercise price per share equal to $ . This prospectus also covers up to 4,115,226 shares of common stock issuable upon conversion of the Series D preferred stock and up to 4,115,226 shares of common stock issuable upon exercise of the warrants.
We have granted the underwriter a 45-day option to purchase up to 1,500 additional shares of Series D preferred stock at a price per share equal to the public offering price of a unit and/or additional warrants to purchase up to an aggregate of 617,284 shares of common stock at a price of $ per warrant, to cover over-allotments, if any.
Their first test will be payment of the $16.6M note due Dec 1st which will occur without difficulty as they have the cash. Future payments will be easier as the new mill is far more cost effective and silver recovery will double.